|
Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes
|
Dec 2013
|
Hematology Am Soc Hematol Educ Program
|
myelodysplastic syndromes (MDS)
|
|
Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights
|
Dec 2013
|
Hematology Am Soc Hematol Educ Program
|
myelodysplastic syndromes (MDS)
|
|
Current concepts in the pathophysiology and treatment of aplastic anemia
|
Dec 2013
|
Hematology Am Soc Hematol Educ Program
|
aplastic anemia
|
|
Allogeneic BM transplantation for the treatment of aplastic anemia: current results and expanding donor possibilities
|
Dec 2013
|
Hematology Am Soc Hematol Educ Program
|
aplastic anemia
|
|
Management of the refractory aplastic anemia patient: what are the options?
|
Dec 2013
|
Hematology Am Soc Hematol Educ Program
|
aplastic anemia
|
|
Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myeloid leukemia following aplastic anemia
|
Dec 2013
|
Biol Blood Marrow Transplant
|
aplastic anemia
|
|
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes
|
Dec 2013
|
Curr Opin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Stem cell origin of myelodysplastic syndromes
|
Dec 2013
|
Oncogene
|
myelodysplastic syndromes (MDS)
|
|
Eltrombopag restores tri-lineage hematopoiesis in refractory severe aplastic anemia which can be sustained on discontinuation of drug
|
Dec 2013
|
Blood
|
aplastic anemia
|
|
How we treat higher-risk myelodysplastic syndromes
|
Dec 2013
|
Blood
|
myelodysplastic syndromes (MDS)
|
